Family · Pharmaceutical analytical standards
Olmesartan
A sartan for hypertension: it blocks the AT1 receptor of angiotensin II, the hormone that narrows blood vessels. Born from research started in Japan in 1990, it reached the market in 2002, first in the United States. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, other impurities and synthesis intermediates.
Did you know?On its own it was barely absorbed (about 4% in rats): chemists turned it into the medoxomil ester, a prodrug that reverts to olmesartan during absorption.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
